Oncolytic virus therapy: A new era of cancer treatment at dawn

Cancer Science

Volumn 107, Issue 10, 2016, Pages 1373-1379

  Fukuhara, Hiroshi ^a   Ino, Yasushi ^b   Todo, Tomoki ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Clinical trial; G47 ; herpes simplex virus; oncolytic immunotherapy; oncolytic virus

Indexed keywords

CG 0070; G 47 DELTA; ONCOLYTIC VIRUS; PELAREOREP; PEXASTIMOGENE DEVACIREPVEC; TALIMOGENE LAHERPAREPVEC; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER PATIENT; GENETIC ENGINEERING; HERPES SIMPLEX VIRUS 1; HUMAN; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; REVIEW; TUMOR IMMUNITY; VIRUS REPLICATION; ADMINISTRATION AND DOSAGE; ADVERSE EFFECTS; ANIMAL; CLINICAL TRIAL (TOPIC); GENE THERAPY; GENE VECTOR; GENETICS; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES; TREATMENT OUTCOME;

ANIMALS; CLINICAL TRIALS AS TOPIC; GENETIC ENGINEERING; GENETIC THERAPY; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; TREATMENT OUTCOME;

EID: 84987814994     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.13027     Document Type: Review

References (79)

1. Larson C, Oronsky B, Scicinski J et al. Going viral: a review of replication-selective oncolytic adenoviruses. Oncotarget 2015; 6: 19976–89.
2. Smith RR, Huebner RJ, Rowe WP, Schatten WE, Thomas LB. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 1956; 9: 1211–8.
3. Hoster H, Zanes R, von Haam E. The association of “viral” hepatitis and Hodgkin's disease. Cancer Res 1949; 9: 473–80.
4. Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol Ther 2007; 15: 651–9.
5. Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signaling. Nat Rev Immunol 2005; 5: 375–86.
6. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991; 252: 854–6.
7. Todo T, Rabkin SD, Sundaresan P et al. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum Gene Ther 1999; 10: 2741–55.
8. Todo T, Rabkin SD, Chahlavi A et al. Corticosteroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replication-competent herpes simplex virus tumor therapy. Hum Gene Ther 1999; 10: 2869–78.
9. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997; 3: 639–45.
10. Xia ZJ, Chang JH, Zhang L et al. Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus. Ai Zheng 2004; 23: 1666–70.
11. Garber K. China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst 2006; 98: 298–300.
12. Coffin R. Interview with Robert Coffin, inventor of T-VEC: the first oncolytic immunotherapy approved for the treatment of cancer. Immunotherapy 2016; 8: 103–6.
13. Andtbacka RH, Kaufman HL, Collichio F et al. Talimogene laherparepvec Improves durable response rate in patients with advanced melanoma. J Clin Oncol 2015; 33: 2780–8.
14. GM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 2006; 12: 6737–47.
15. Chou J, Roizman B. The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells. Proc Natl Acad Sci USA 1992; 89: 3266–70.
16. He B, Chou J, Brandimarti R et al. Suppression of the phenotype of gamma(1)34.5-herpes simplex virus 1: failure of activated RNA-dependent protein kinase to shut off protein synthesis is associated with a deletion in the domain of the alpha47 gene. J Virol 1997; 71: 6049–54.
17. Liu BL, Robinson M, Han ZQ et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 2003; 10: 292–303.
18. Markert JM, Parker JN, Buchsbaum DJ et al. Oncolytic HSV-1 for the treatment of brain tumours. Herpes 2006; 13: 66–71.
19. Agarwalla PK, Aghi MK. Oncolytic herpes simplex virus engineering and preparation. Methods Mol Biol 2012; 797: 1–19.
20. Goldsmith K, Chen W, Johnson DC et al. Infected cell protein (ICP)47 enhances herpes simplex virus neurovirulence by blocking the CD8+ T cell response. J Exp Med 1998; 187: 341–8.
21. Früh K, Ahn K, Djaballah H et al. A viral inhibitor of peptide transporters for antigen presentation. Nature 1995; 375: 415–8.
22. York IA, Roop C, Andrews DW et al. A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes. Cell 1994; 77: 525–35.
23. Poppers J, Mulvey M, Khoo D et al. Inhibition of PKR activation by the proline-rich RNA binding domain of the herpes simplex virus type 1 Us11 protein. J Virol 2000; 74: 11215–21.
24. Senzer NN, Kaufman HL, Amatruda T et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009; 27: 5763–71.
25. Kaufman HL, Kim DW, DeRaffele G et al. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 2010; 17: 718–30.
26. Mineta T, Rabkin SD, Yazaki T et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995; 1: 938–43.
27. Todo T, Martuza RL, Rabkin SD et al. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci USA 2001; 98: 6396–401.
28. Aghi M, Visted T, Depinho RA et al. Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16. Oncogene 2008; 27: 4249–54.
29. Kaur B, Chiocca EA, Cripe TP. Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress. Curr Pharm Biotechnol 2012; 13: 1842–51.
30. Liu R, Martuza RL, Rabkin SD. Intracarotid delivery of oncolytic HSV vector G47Delta to metastatic breast cancer in the brain. Gene Ther 2005; 12: 647–54.
31. Varghese S, Rabkin SD, Liu R et al. Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers. Cancer Gene Ther 2006; 13: 253–65.
32. Fukuhara H, Ino Y, Kuroda T et al. Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system. Cancer Res 2005; 65: 10663–8.
33. Fukuhara H, Martuza RL, Rabkin SD et al. Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma. Clin Cancer Res 2005; 11: 7886–90.
34. Prabhakar S, Messerli SM, Stemmer-Rachamimov AO et al. Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47Delta. Cancer Gene Ther 2007; 14: 460–7.
35. Wang JN, Hu P, Zeng MS et al. Anti-tumor effect of oncolytic herpes simplex virus G47delta on human nasopharyngeal carcinoma. Chin J Cancer 2011; 30: 831–41.
36. Wang J, Xu L, Zeng W et al. Treatment of human hepatocellular carcinoma by the oncolytic herpes simplex virus G47delta. Cancer Cell Int 2014; 14: 83.
37. Hoffmann D, Bangen JM, Bayer W et al. Synergy between expression of fusogenic membrane proteins, chemotherapy and facultative virotherapy in colorectal cancer. Gene Ther 2006; 13: 1534–44.
38. Antoszczyk S, Spyra M, Mautner VF et al. Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus. Neuro Oncol 2014; 16: 1057–66.
39. Wang JN, Xu LH, Zeng WG et al. Treatment of human thyroid carcinoma cells with the g47delta oncolytic herpes simplex virus. Asian Pac J Cancer Prev 2015; 16: 1241–5.
40. Cheema TA, Wakimoto H, Fecci PE et al. Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. Proc Natl Acad Sci USA 2013; 110: 12006–11.
41. Ino Y, Todo T. Clinical development of a third-generation HSV-1 (G47∆) for malignant glioma. Gene Ther Regul 2010; 5: 101–11.
42. Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 2009; 9: 64–71.
43. Kim JH, Oh JY, Park BH et al. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther 2006; 14: 361–70.
44. Parato KA, Breitbach CJ, Le Boeuf F et al. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther 2012; 20: 749–58.
45. Park BH, Hwang T, Liu TC et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 2008; 9: 533–42.
46. Breitbach CJ, Bruke J, Jonker D et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 2011; 477: 99–102.
47. Heo J, Reid T, Ruo L et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 2013; 19: 329–36.
48. Ramesh N, Ge Y, Ennist DL et al. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor–armed oncolytic adenovirus for the treatment of bladder cancer. Clin Cancer Res 2006; 12: 305–13.
49. Zwicker J, Müller R. Cell cycle-regulated transcription in mammalian cells. Prog Cell Cycle Res 1995; 1: 91–9.
50. Burke JM, Lamm DL, Meng MV et al. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J Urol 2012; 188: 2391–7.
51. Packiam VT, Campanile AN, Barocas DA et al. A phase II/III Trial of CG0070, an oncolytic adenovirus, for BCG-refractory non-muscle-invasive bladder cancer (NMIBC). J Urol 2016; 195: e142.
52. Vidal L, Yap TA, White CL et al. Reovirus and other oncolytic viruses for the targeted treatment of cancer. Target Oncol 2006; 1: 130–50.
53. Hashiro G, Loh PC, Yau JT. The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch Virol 1977; 54: 307–15.
54. Duncan MR, Stanish SM, Cox DC. Differential sensitivity of normal and transformed human cells to reovirus infection. J Virol 1978; 28: 444–9.
55. Norman KL, Hirasawa K, Yang AD, Shields MA, Lee PW. Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc Natl Acad Sci USA 2004; 101: 11099–104.
56. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682–9.
57. Gong J, Sachdev E, Mita AC, Mita MM. Clinical development of reovirus for cancer therapy: an oncolytic virus with immune-mediated antitumor activity. World J Methodol 2016; 6: 25–42.
58. Gollamudi R, Ghalib MH, Desai KK et al. REO-001: intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients in advanced solid tumors. Invest New Drugs 2010; 28: 641–9.
59. Thirukkumaran CM, Nodwell MJ, Hirasawa K et al. Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic. Cancer Res 2010; 70: 2435–44.
60. Kicielinski KP, Chiocca EA, Yu JS, Gill GM, Coffey M, Markert JM. Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults. Mol Ther 2014; 22: 1056–62.
61. Adair RA, Roulstone V, Scott KJ et al. Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. Sci Transl Med 2012; 4: 138ra77.
62. Ocean AJ, Bekaii-Saab TS, Chaudhary I et al. A multicenter phase I study of intravenous administration of reolysin in combination with irinotecan/fluorouracil/leucovorin (FOLFIRI) in patients (pts) with oxaliplatin-refractory/intolerant KRAS-mutant metastatic colorectal cancer (mCRC). J Clin Oncol 2013; 31: 2318.
63. Sborov DW, Nuovo GJ, Stiff A et al. A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma. Clin Cancer Res 2014; 20: 5946–55.
64. Karapanagiotou EM, Roulstone V, Twigger K et al. Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin Cancer Res 2012; 18: 2080–9.
65. Phelps M, Cohn DE, O'Malley DM et al. Reovirus replication in ovarian and peritoneal tumors after intravenous administration. Cancer Res 2010; 70: 2594.
66. Saunders M, Anthoney A, Coffey M et al. Results of a phase II study to evaluate the biological effects of intratumoral (ITu) reolysin in combination with low dose radiotherapy (RT) in patients (Pts) with advanced cancers. J Clin Oncol 2009; 27: e14514.
67. ®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma. Mol Ther 2012; 20: 1998–2003.
68. Karnad A, Haigentz M, Miley T, Coffey M, Gill G, Mita M. A phase II study of intravenous wild-type reovirus (Reolysin) in combination with paclitaxel plus carboplatin in patients with platinum refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. Mol Cancer Ther 2011; 10: C22.
69. Mita AC, Argiris A, Coffey M, Gill GM, Mita M. A Phase 2 study of intravenous administration of Reolysin (R) (Reovirus Type 3 Dearing) in combination with paclitaxel (P) and carboplatin (C) in patients with squamous cell carcinoma of the lung. J Thorac Oncol 2013; 8: S617–8.
70. Russell SJ, Federspiel MJ, Peng KW et al. Remission of disseminated cancer after systemic oncolytic virotherapy. Mayo Clin Proc 2014; 89: 926–33.
71. Hirasawa K, Nishikawa SG, Norman KL et al. Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res 2003; 63: 348–53.
72. White CL, Twigger KR, Vidal L et al. Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. Gene Ther 2008; 15: 911–20.
73. Rajani K, Parrish C, Kottke T et al. Combination therapy with reovirus and anti-PD-1 blockade controls tumor growth through innate and adaptive immune Responses. Mol Ther 2016; 24: 166–74.
74. Puzanov IMM, Andtbacka RH, Minor DR et al. Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. J Clin Oncol 2015; 33(Suppl): 9063.
75. Harrington KJ, Puzanov I, Hecht JR et al. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy. Expert Rev Anticancer Ther 2015; 15: 1389–403.
76. Ino Y, Saeki Y, Fukuhara H et al. Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy. Clin Cancer Res 2006; 12: 643–52.
77. Liu TC, Zhang T, Fukuhara H. Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy. Mol Ther 2006; 14: 789–97.
78. Liu TC, Zhang T, Fukuhara H et al. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors. Clin Cancer Res 2006; 12: 6791–9.
79. Tsuji T, Nakamori M, Iwahashi M et al. An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhanced in vivo antitumor effect against human gastric cancer. Int J Cancer 2013; 132: 485–94.